总法律顾问
Jonathan E. Anderman, JD, is Senior Vice President, General Counsel, and Corporate Secretary at Compass Therapeutics, Inc. (CMPX), a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics.[[1]](https://in.marketscreener.com/insider/JONATHAN-ANDERMAN-A3KFEK/)[[2]](https://www.compasstherapeutics.com/about/)[[3]](https://theorg.com/org/compass-therapeutics/org-chart/jonathan-anderman) He joined the company in August 2021, overseeing legal, corporate governance, and compliance functions, and has recently engaged in insider trading, including purchasing 25,000 shares at $1.89 each and holding approximately 46,000 shares valued at $243,340 as of March 31, 2026.[[1]](https://in.marketscreener.com/insider/JONATHAN-ANDERMAN-A3KFEK/)[[7]](https://www.investing.com/news/insider-trading-news/compass-therapeutics-general-counsel-jonathan-anderman-buys-47250-in-stock-93CH-4651137)[[8]](https://insiderinsights.com/free/index.php?s=ticker&o=-1&a=&q=CMPX)
Anderman brings extensive experience in healthcare and life sciences law. Prior to Compass, he served as Global Commercial Counsel at Biogen, Inc. (2020-2021) and Assistant General Counsel at Intarcia Therapeutics, Inc. (2018), advising on corporate transactions, commercialization, and compliance.[[1]](https://in.marketscreener.com/insider/JONATHAN-ANDERMAN-A3KFEK/)[[3]](https://theorg.com/org/compass-therapeutics/org-chart/jonathan-anderman) Earlier, he was a healthcare attorney at Holland & Knight, representing clients on regulatory and transactional matters.[[3]](https://theorg.com/org/compass-therapeutics/org-chart/jonathan-anderman) He earned his JD from Boston University School of Law and BA from The Pennsylvania State University.[[1]](https://in.marketscreener.com/insider/JONATHAN-ANDERMAN-A3KFEK/)[[3]](https://theorg.com/org/compass-therapeutics/org-chart/jonathan-anderman)
查看完整内部人档案 →